Myeloma Crowd Radio

Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.



      episode 9: Myeloma Crowd: Paul Richardson, MD, Dana Farber Cancer Institute

      The myeloma landscape is rapidly changing with many new advancements. Paul Richardson, MD of the Dana Farber Cancer Institute joins Myeloma Crowd Radio to share recent updates from major summer meetings including the American Society of Clinical Oncology and European Hematology Association meeting and several others.  Thanks to our episode sponsor, Takeda Oncology. 



      episode 8: Myeloma Crowd Radio: Brian McMahon of SparkCures (rescheduled)

      How do multiple myeloma patients get into clinical trials? Especially those using popular new science like CAR T therapy? Brian McMahon, founder of SparkCures shares tips and tricks to get into these trials. Brian is the founder of SparkCures, a multiple myeloma clinical trial finder tool that simplifies the process. Brian shares his experience helping individual myeloma patients join these trials and will share the ins and outs of clinical trial participation. Join us and call in with...



      episode 6: Myeloma Crowd Radio: Muhamed Baljevic, MD, University of Nebraska Medical Center

      Many multiple myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Researchers found that expression of MUC20 could help predict how sensitive or resistant patients would be to proteasome inhibitors and found that MUC20 protein could be potentially impacted by an already FDA-approved drug offered by Amgen.  Learn more from Dr. Muhamad Baljevic of the University of Nebraska Medical Center about how this new drug is being used in a Phase ...


       2018-05-28  1h6m

      episode 5: Myeloma Crowd Radio: HealthTree With Rafael Fonseca, MD, Mayo Clinic

      A new tool for multiple myeloma patients is coming in June! Join us as we discuss the Myeloma Crowd's new initiative called HealthTree with Rafael Fonseca, MD of the Mayo Clinic in Scottsdale.  HealthTree will help myeloma patients understand their personally relevant treatment options, find clinical trials, track lab data and help accelerate research towards a cure.   Over 80% of myeloma patients are treated by general oncologists, yet data shows that patients who see myeloma specilists ca...


       2018-05-18  1h7m

      episode 4: Myeloma Crowd Radio: Luciano Costa, MD, PhD, University of Alabama

      Adequate treatment of multiple myeloma at diagnosis is a key issue for patients because their first remission is typically the longest and most durable. Dr. Luciano Costa of the University of Alabama joins Myeloma Crowd Radio to discuss a trial testing some of the best therapies for myeloma up-front: lenalidomide, dexamethasone, carfilzomib and daratumumab followed by a stem cell transplant. The same four drugs will be used after transplant as "consolidation" therapy. The goal is to ...


       2018-04-16  1h0m

      episode 3: Myeloma Crowd Radio: Veronika Bachanova, MD, PhD, University of Minnesota

      Natural killer cells are the body's way of eliminating cancerous cells. When a myeloma patient's immune system is too weak, the natural killer cells can't effectively do their job to eliminate myeloma. A study is now being done to test donor natural killer cells in relapsed myeloma patients. The natural killer cells are collected and combined with IL-2 to help them grow and expand. Elotuzumab is used to help the NK cells migrate to the myeloma tumor and has anti-myeloma effect on its own. ...


       2018-03-12  51m

      episode 2: Myeloma Crowd Radio: William Matsui, MD, Johns Hopkins University

      Allogeneic stem cell transplant was the first ever immunotherapy available for mulitple myeloma patients. Dr. Matsui shares how the Johns Hopkins allo transplant procedure has significantly improved safety concerns. His research is now focused on extending and deepening remissions with a new immunotherapy antibody given with transplant. Dr. Matsui will also share his latest research on precursor myeloma cells (called myeloma stem cells) and how they can be targeted before growing into full ...

      this episode is not available


       2018-02-16  1h10m

      Myeloma Crowd Radio: Martin Kaiser, MD, The Institute of Cancer Research, UK

      Dr. Martin Kaiser joins Myeloma Crowd Radio to share more about the latest advances in myeloma treatment in the United Kingdom and how the use of myeloma genomic data with thousands of patients in the UK is furthering new insights in myeloma care.    Thanks to our episode sponsor, SparkCures. SparkCures provides an easy way to find and join multiple myeloma clinical trials. 


       2018-02-11  39m

      episode 1: Myeloma Crowd Radio: Robert Orlowski, MD, PhD, MD Anderson Cancer Center

      The year 2018 promises to be an exciting one in multiple myeloma research. Learn what about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. With the explosion of immunotherapy and combination approaches now in the clinic and in clinical trials,  the choices are greatly expanding for myeloma patients. Listen to myeloma expert Robert Z. Orlowski, MD, PhD of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the ...


       2018-01-05  1h4m

      episode 1: Myeloma Crowd Radio: Diahanna Valentine, Critical Care Financial Consulting

      Multiple myeloma treatment can cause "financial toxicity" for patients who are trying to pay for care that will give them optimal outcomes. Diahanna Valentine joins the Myeloma Crowd to discuss financial resources that are available to myeloma patients in this informative. show.  Diahanna is Owner and Founder of Critical Care Financial Consulting, LLC which takes a holistic approach to managing your finances in the face of a critical or chronic illness. She is an 18+ year Financial Advisor, ...


       2017-10-17  1h3m